Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explored the epigenetic mechanisms of dermal fibroblast progenitor differentiation and found that the repressive chromatin profile from H3K27me3 prevents these progenitors from reforming skin in allograft assays, despite their multipotent potential.

In this split-scalp study, researchers observed that combining fractional CO2 laser and PRP treatment was significantly more effective in improving hair parameters in women with female pattern hair loss than using each intervention alone or placebo.

This study found that tissue transcriptomics and a normalization approach can effectively cluster nine inflammatory skin diseases and identify specific biomarkers, including PTEN as a marker for cutaneous lupus erythematosus.

This study suggests that linalool, a common allergen in personal care products, may contribute to frontal fibrosing alopecia pathogenesis by triggering immune responses and depleting hair follicle stem cells, especially in sensitized individuals.

Reducing SFRP1 can promote hair growth and may help treat hair loss.

In this study, Trf1 genetic deletion in mice, including those with cancer-prone mutations, was shown to not affect overall viability and cause only mild effects, while being necessary for tumor formation, suggesting a potential therapeutic window for Trf1 as an anti-cancer target.

GLABRA2 represses root hair formation by inhibiting a specific gene.

This article discusses the case of a 59-year-old woman with a history of progressive facial hyperpigmentation and explores potential connections between her condition and her family history, but reports no clinical findings.

This case report highlights a female patient with familial partial lipodystrophy who showed significant improvement in liver stiffness after starting leptin replacement therapy.

In this study, researchers used advanced RNA sequencing techniques to discover that communication between specific fibroblast and myeloid cell populations may play a role in acne keloidalis, and found that corticosteroid injections could significantly reduce disease activity and gene expression related to these cells.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This study identified SFRP2 and PTGDS as potential biomarkers for female pattern hair loss, finding these genes consistently upregulated in bald hair follicles from all 18 patients, which may contribute to understanding the condition's pathogenesis and developing targeted treatments.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

In this study, researchers demonstrated that treating platelet rich plasma with microsecond pulsed electric fields effectively activates platelets and induces similar or higher growth factor release compared to traditional bovine thrombin, suggesting a potential clinical use that may be more cost-effective and practical.

PRSS35 enzyme may help start skin tumors and could be a target for cancer treatment.

This study identified mutations in the FGF5 gene as a cause of extreme eyelash growth in Pakistani families, highlighting a potential target for regulating eyelash growth.

The researchers reported that disrupting the RPGRIP1L gene in mice impaired desmosome function, causing skin blistering, and their findings suggest that PKCβII inhibition could help treat pemphigus.

Folliculin slows hair growth, and blocking it might help treat hair loss.

In this study, researchers examined a patient with ZMYM2::FGFR1 fusion-positive leukemia, finding that Pemigatinib showed efficacy, while Ponatinib resistance was linked to a specific FGFR1 mutation. Other FGFR inhibitors demonstrated high effectiveness in ex vivo assays.

In this study, researchers found that the pCLCA2 protein is expressed in specific areas of pig skin, but its role in skin structure or function remains unclear.

This article discusses the characteristics of lichen planus pigmentosus and frontal fibrosing alopecia but reports no new clinical findings; the authors review existing knowledge.

Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.

In this study, researchers found that reducing FGF20 expression in dermal papilla cells of fine-wool sheep impedes the growth and differentiation of hair follicle stem cells, providing insights into wool trait improvement and regenerative medicine applications.

This study suggests that allergens like linalool found in personal care products may contribute to the pathobiology of frontal fibrosing alopecia by affecting immune responses and stem cell function in hair follicles.

This study found that the FER/MLO signaling module plays a crucial role in calcium oscillations and ROS production in root hair tip growth, with the MLO15 protein regulating these processes and restoring disrupted growth and signaling in fer mutant root hairs.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

This study found that HIF-P4H-2 function in FoxD1-lineage cells is crucial for normal hair follicle development and homeostasis in mice, implicating disrupted HIF, TGF-β, and Notch signaling pathways in associated defects.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

In this study, the researchers identified CEP135 as a biomarker linked to poor sarcoma survival and suggested PLK1 as a potential therapeutic target for sarcoma patients with high CEP135 expression.